Foto di copertina di Innogest Capital
Innogest Capital

Innogest Capital

Mandanti di venture capital e private equity

Milan, Lombardia 6.963 follower

Investors in companies that make the difference, partner of entrepreneurial visionaries

Chi siamo

We are investors in companies that make the difference. We trust in great entrepreneurs, we partner with hard-working visionaries. Innogest is a Venture Capital firm focused on seed and early stage ventures, with more than € 200 milion of capital under management. We have over 100 years of cumulative professional experience in the digital and the healthcare fields. Innogest invests in high potential companies through a direct share in their equity and pays special attention to market potential and size. Innogest leverages its extensive network of contacts, working alongside its partners through its offices in Turin, Milan and San Francisco. Our mission is to generate high-level returns for our investors by turning entrepreneurship and technology into fast-growing and successful companies.

Settore
Mandanti di venture capital e private equity
Dimensioni dell’azienda
11-50 dipendenti
Sede principale
Milan, Lombardia
Tipo
Società privata non quotata
Data di fondazione
2006
Settori di competenza
Venture Capital, Early Stage, Healthcare, Cardiovascular, Neurology, Oncology, Digital Health, Digital, Fintech, Foodtech, Fashion tech e Travel

Località

Dipendenti presso Innogest Capital

Aggiornamenti

  • Visualizza la pagina dell’organizzazione Innogest Capital

    6.963 follower

    🚀 We’re thrilled to support Newronika S.p.A. in its €13.6M Series B round, fueling the future of adaptive neuromodulation. Their groundbreaking technology is set to change the game for people living with neurological disorders. Huge congrats to the Newronika team and our fellow investors for this milestone! 🎉 #Innovation #MedTech #Neuromodulation #VentureCapital #Newronika #Innogest

    Visualizza la pagina dell’organizzazione Newronika S.p.A.

    4.094 follower

    🚀 A Major Milestone for Newronika: €13.6M Series B Financing Secured We are proud to announce the successful closing of our €13.6 million Series B funding round, led by Fondazione ENEA Tech e Biomedical, with participation from Indaco Venture Partners SGR, Innogest Capital SGR, Wille Finance, TNBT Capital, and F3F. This funding will accelerate the development and commercialization of our AlphaDBS system, the world’s most advanced adaptive deep brain stimulation (aDBS) technology, designed to transform the treatment of Parkinson’s disease and other neurological disorders. Unlike conventional DBS, AlphaDBS dynamically adjusts stimulation in real time, optimizing therapy for each patient based on their brain signals. With Parkinson’s disease affecting over 8.5 million people worldwide, this investment brings us closer to making a tangible difference in patients’ lives by delivering next-generation, data-driven therapy that improves outcomes and quality of life. 🌍 A huge thank you to our investors and partners for believing in our vision of transforming neuromodulation. We are just getting started! 🔗 Read the full press release below #Newronika #SeriesB #AdaptiveDBS #AlphaDBS #Neuromodulation #ParkinsonsDisease #MedicalInnovation #Neurotechnology

Pagine simili

Sfoglia le offerte di lavoro